Overview

Spinal Cord Injury Neuroprotection With Glyburide

Status:
Not yet recruiting

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.

Phase:

Phase 1

Details

Lead Sponsor:

University of Kentucky

Treatments:

Glyburide